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Background: Mechanical thrombectomy (MT) of ischemic stroke was demonstrated to be effective in 
clinical trials and was reported to have favorable outcomes in real clinical settings since 2015. We aimed to 
determine the national trends of MT and compare the outcomes between the different levels of treating 
hospital.
Methods: We obtained data from the nationwide database from 2008 to 2017. Patients with ischemic stroke 
who received MT were identified using the International Classification of Disease Codes. Good outcome was 
defined as discharge to home, and a poor outcome was defined as cerebral hemorrhage, physical disability, 
or death. The study period was divided into three (off-label MT, transitional, MT period). Hospital groups 
where MT was performed were divided into tertiary and non-tertiary hospitals.
Results: In MT period, 47.0% of the MT procedures were performed in non-tertiary hospitals compared 
with 36.1% in off-label MT period. Comparison of the 3-month mortality between patients who were 
treated in tertiary vs. non-tertiary hospitals revealed significant lower mortality in tertiary hospital through 
all period. The incidence of cerebral hemorrhage and physical disability did not differ between hospital 
groups. However, the percentage of patients discharged home was 41.4% for tertiary hospitals and 42.4% for 
non-tertiary hospitals, which was not statistically different in MT period (P=0.4671).
Conclusions: Analysis of the nationwide data confirmed that the extent of increase in MT was higher 
in non-tertiary hospitals than tertiary hospitals. In addition, no significant difference was revealed in the 
number of favorable clinical outcome between the hospital groups during MT period.
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Introduction
Mechanical thrombectomy (MT) has become the standard 
procedure in 2015 (1), and previous studies showed that 
indications for MT have been increasing (2,3). Currently, 
MT is recommended for patients who develop neurologic 
deficit less than 24 hours after the occlusion of the 
anterior circulation (4). MT was first performed in 2005, 
and the number of cases has dramatically increased after 
2015. The number of hospitals that provide MT has also 
increased (5). Performing MT at the earliest time possible 
increases the chance of a good prognosis for patients with 
acute ischemic stroke (6). Therefore, an increase in the 
number of hospitals performing this procedure will likely 
result in an increased number of patients with a favorable 
prognosis. Indeed, previous studies reported improved 
prognoses in real-world clinical settings after the recent 
guideline changes (7,8).
The prognosis will likely improve if a patient with acute 
ischemic stroke receives the procedure as early as possible. 
Previously, multiple studies categorized hospitals into 
comprehensive stroke centers (CSC) and primary stroke 
centers (PSC) based on the treatments available (9) and what 
system of treatments were effective (10). In South Korea, 
there are 11 designated Regional Cardiocerebrovascular 
Centers under the Ministry of Health and Welfare. All these 
hospitals are CSC (11), and none are a PSC. Because these 
centers are insufficient for treating all patients with acute 
ischemic stroke, currently, patients undergo treatment in 
other hospitals. Korean hospitals are categorized as tertiary 
hospitals and non-tertiary hospitals based on the number 
of beds, medical departments, and the ratio of severely ill 
patients. Out of the 11 CSC, 9 are tertiary hospitals; the 
tertiary hospitals that are not CSC are referral hospitals, so 
many patients with acute ischemic stroke are seen at referral 
hospitals, and the frequency of MT is higher than in non-
tertiary hospitals. The Joint Commission, in conjunction 
with the Association/American Stroke Association, added 
that at least 15 cases of MT are performed annually as a 
qualification for a CSC (12). A previous study reported that 
the prognosis might be improved by receiving treatment 
at a tertiary hospital because the mortality rate was lower 
for patients treated in hospitals that performed many MT 
procedures (13).
The present study aimed to verify whether the number 
of MT procedures performed in tertiary and non-tertiary 
hospitals changed over time because there is still no 
apparent difference between CSC and PSC in South Korea. 
We also investigated whether there was a difference in 
patient prognosis after MT for different hospital types. 
We present the following article in accordance with the 
STROBE reporting checklist (available at https://dx.doi.
org/10.21037/atm-21-2342).
Methods
Databases and study population
We selected subjects from the data of the Korean National 
Health Insurance, to which 97% of the Korean population 
is registered. We extracted all insurance claims data between 
2007–2017 for patients who were >45 years old and claimed 
a history of hospitalization under cerebral infarction 
(ICD-10 code: I63) as the main diagnosis or the first sub-
diagnosis. Considering the washout time, we excluded data 
from the year 2007. We sorted these data by procedure 
codes related to thrombectomy. Before June 30, 2017 in 
Korea, these codes were M6631 and M6633. Later, these 
codes were subdivided from M6631 to M6630 and M6635 
and from M6633 to M6636 and M6637, depending on the 
location of occluded vessel. Then, we reviewed whether 
these patients used tissue plasminogen activator (tPA) at the 
time of thrombectomy. From these data, we checked for the 
product codes 223501BIJ or 223502BIJ.
Outcome variables
Good outcomes were defined as patients who were 
discharged home after 30 days without significant issues, 
such as death or re-hospitalization. To screen patients 
with good outcomes, we tracked the patients who were 
discharged home after hospitalization for stroke treatment 
with an insurance claim. To increase the reliability of good 
outcomes, we excluded those who had died within 30 days 
of discharge and those who had claimed re-hospitalization 
under either ICD-10 codes I63 or I61 within 30 days of 
discharge because their prognosis was expected to be poor 
even if they experienced recurrence or were hospitalized 
again for rehabilitation. Since readmission within 30 days 
was used as a criterion to evaluate the quality of medical 
care in the previous study (14), the same period was applied 
as the criterion in this study.
Poor outcomes were defined as cerebral hemorrhage 
following the procedure, significant disability, and death. 
To identify the incidence rate of a cerebral hemorrhage, 
we screened patients with insurance claims of ICD-10 
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code I61 as the principal diagnosis, the first sub-diagnosis, 
or with a procedure code related to cerebral hemorrhage 
within 30 days of MT. We defined the following cases as 
cerebral hemorrhage outcome variables: (I) when a new 
hospitalization claim was identified with I61 as the main 
or first sub-diagnosis within 30 days of the hospitalization 
episode in which the MT claimed, (II) when the first sub-
diagnosis with I61 was identified with I63 as the principal 
diagnosis after MT.
The procedure codes used for screening were N0322 
(burr Hole), N0333 (craniectomy), and S4756/S4622 
(hematoma removal). We tracked deaths within three 
months and deaths within one year of treatment through 
mor tality data. In South Korea, disability can be registered 
when at least six months have passed from the time of the 
stroke event, permitting those patients who had registered 
for the cerebral injury disability.
Analysis
We divided patients into a tertiary hospital group or non-
tertiary hospital group depending on the hospital level 
to investigate annual changes in treatment outcomes 
in each hospital group. In order to reveal the annual 
prognosis change, we analyzed 3-month mortality, cerebral 
hemorrhage, and home discharge rates by 2017, since we 
were unable to track the mortality or the state of disability 
registration for the cerebral injury within one year from the 
selected data. 
Consequently, we analyzed subjects and outcome 
variables by period and group of hospitals. We classified 
the patients based on the period when MT was performed. 
The period when the stent-retriever was used off-label in 
South Korea was estimated to be October – December of 
2010 (15). The stent-retriever was not reimbursed by the 
Korean National Health Insurance between May 2013 – 
July 2014, even though its usage was officially approved. 
Therefore, we categorized the periods as “off-label MT 
period (2008.01–2010.12)” when the stent-retriever was 
rarely used, “transitional period (2011.01–2014.07)” when we 
could not precisely identify stent-retriever usage, and “MT 
period (2014.08–2016.12)” when the insurance claims data 
verified the frequency of stent-retriever use. The 2017 data 
were excluded from the MT period because the information 
on disability registration was unavailable.
In the previous study based on the Korean National 
Health Insurance Data, hospitals that performed 18 or less 
annual MT were in the bottom quarter (16). The CSC's 
eligibility criteria is 15 or more MTs per year in hospitals (12). 
Therefore, in this study, the prognosis depending on the 
MT volume for each hospital was analyzed as a confounding 
variable whether or not hospitals that perform MT more 
than 18 per year. Also, we identified the comorbidities 
hypertension, diabetes mellitus, dyslipidemia, and atrial 
fibrillation that might increase the risk of stroke and thus 
affect the prognosis and the risk factors of patients from 
the insurance claims data before MT treatment and during 
hospitalization for MT. Therefore, we analyzed the Charlson 
Comorbidity Index (CCI) of subjects to verify the influence 
of comorbidities on death.
Neurologic defict severity assessed using NIH Stroke 
Scale (NIHSS) is known as the most important factor for 
predicting the prognosis of ischemic stroke patient (17). 
However, NIHSS cannot be identified in claim data for 
which no clinical information is available. In order to 
supplement the limitations of the claim data study, a stroke 
severity index (SSI) that can be substituted for the NIHSS 
was proposed (18). In other study using claim data such as our 
study, the SSI was calculated using the claims presented in the 
previous study and validated based on real clinical data (16). 
We also calculated the SSI using the same items and 
coefficients (16), analyzed whether there was a difference 
between hospital groups, and included it as a confounding 
variable in the prognosis analysis.
The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). This study 
was approved by the Institutional Review Board of 
the National Health Insurance Service Ilsan Hospital 
(NHIMC 2019-01-006). The need for written informed 
consent was waived as patient identification data were 
removed from the database used.
Statistical analysis
SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used for 
data analysis, and the one-way ANOVA and the chi-square 
test were used to compare descriptive statistics and the 
frequency of various factors. To confirm the difference in 
the trend of the outcome variables by year, we conducted 
Cochran-Armitage Trend test. To compare the distribution 
of baseline covariates between hospitals, we used the chi-
square test. For the identification of the risk of death and 
cerebral injury disability, time-dependent Cox proportional 
hazard regression analysis was applied. For the identification 
of factors relating to discharge-to-home patients, multiple 
logistic regression analysis was used. P values <0.05 for two-
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sided tests were considered statistically significant. 
Results
The number of tertiary hospitals that provided MT did not 
change significantly between 2008 and 2015 (39 in 2008 
to 42 in 2017). In contrast, the number of non-tertiary 
hospitals that provided MT was 46 in 2008, which increased 
gradually to 92 in 2017 (Figure 1). In 2008, about 37% of 
MT was performed at non-tertiary hospitals, whereas, in 
2017, almost half of MT was done at non-tertiary hospitals. 
In 2014, 565 patients underwent the MT procedure at non-
tertiary hospitals, and in 2015, 959 underwent MT. The 
largest annual increase rate was 70% (Figure 2).
The annual trend showed an increased proportion of 
patients with good outcomes and a reduced proportion of 
patients with poor outcomes in both hospital groups (Figure 3). 
In the trend analysis, there was no statistical difference 
in the 3-month mortality rate and home discharge rate 
between hospital groups. The percentage of patients 
discharged home from tertiary versus non-tertiary hospitals 
was 36.9% versus 34.4% in 2008, and 43.1% versus 40.2% 
in 2017—the highest rate was in 2016. The 3-month 
mortality rate was 28.8% and 24.4% in 2008, and 17.0% 
and 18.1% in 2017, respectively. A gradual decrease of the 
ratio of patients receiving surgery for cerebral hemorrhage 
within 30 days between 2008 and 2017 was 7.2% to 1.3% 
and 6.3% to 3.0% for tertiary and non-tertiary hospitals, 
respectively.
In off-label MT period, 36.1% of MT was performed 
at non-tertiary hospitals, whereas, in MT period, 47.0% 
of MT was done at non-tertiary hospitals. Of note, patient 
age was significantly higher in tertiary hospitals during the 
transitional period, but there was no statiscally significant 
difference during other periods. The prevalence of atrial 
fibrillation, which is the most frequent comorbidity, 
was higher in tertiary hospitals regardless of the period. 
Dyslipidemia occurred more frequently in tertiary hospitals 
except during the off-label MT period. The mean value of 
SSI was statistically higher in non-tertiary hospitals than in 
tertiary hospitals during all period, but the median values 
differed only during the off-label period (Table 1). Mortality 
rates were higher in non-tertiary hospitals than in tertiary 
hospitals for all periods; the rate decreased in the order of 
off-label MT period, transitional period, and MT period. 
The percentage of surgery for cerebral hemorrhage or 
disability registration tended to decrease gradually, and 
there was no statistical difference between the hospital 
groups for all periods. The rate of home discharge for 
the MT period was not statistically different between the 
hospital groups.
In the MT period, 87.1% of the patients were treated at 
the tertiary hospital with an annual volume of MT greater 
than 18, and 48.2% of the patients were treated at the non-
tertiary hospital with the same MT volume. The proportion 
of patients treated in hospitals with MT volume exceeding 
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Figure 2 Annual trends of the number and proportion of patients treated for ischemic stroke with endovascular therapy by hospital group.
Figure 3 Annual trends of outcomes of endovascular therapy by hospital group from 2008 to 2017. The P value of the Cochran-Armitage 





























2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Calendar year

































2009 2010 2011 2012 2013 2014 2015 2016 2017
Calendar year
Seo et al. Outcomes of mechanical thrombectomy by hospital levels
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2021;9(15):1227 | https://dx.doi.org/10.21037/atm-21-2342















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Annals of Translational Medicine, Vol 9, No 15 August 2021 Page 7 of 11



















































































































































































































































































































































































































































































































































































































Seo et al. Outcomes of mechanical thrombectomy by hospital levels
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2021;9(15):1227 | https://dx.doi.org/10.21037/atm-21-2342
Page 8 of 11
18 increased by 23.7% in the tertiary hospital and 30.6% in 
the non-tertiary hospital compared to the previous period 
in the MT period, showing a larger increase in the non-
tertiary hospital.
The risk of death was significantly higher in the 
non-tertiary hospital than in the tertiary hospital for 
the transitional period [hazard ratio (HR) 1.096, 95% 
confidence interval (CI): 1.004–1.195, P=0.04] and MT 
period (HR 1.156, 95% CI: 1.052–1.27, P=0.0026). 
However, it was not significant when we adjusted for 
confounding variables that included MT volume and 
SSI. The risk of disability was significantly higher in the 
non-tertiary hospital than in the tertiary hospital for MT 
period (HR 1.192, 95% CI: 1.061–1.34, P=0.0032). It was 
also not significant in the adjusted analysis (HR 1.091, 
95% CI: 0.96–1.24, P=0.183). The adjusted odds ratio 
(OR) for discarhge to home in the transitional period was 
0.812 when we compared non-teritiary hospitals with 
tertiary hospitals (OR 0.694–0.949, P=0.009). This ratio 
was inverted in the MT period. The adusted OR for home 
discharge during MT period was 1.36 when compared 
non-tertiary hospitals vs. tertiary hospitals (CI: 1.19–1.555, 
P<0.0001) (Table 2).
Discussion
Our analysis of nationwide data showed that the usage 
of MT markedly increased since 2015 when there was a 
substantial change in the clinical guidelines. The increase 
rate was higher in non-tertiary hospitals than in tertiary 
hospitals. Following the increase of MT procedures, the 
number of hospitals providing MT have increased gradually. 
The reasons for the increase in MT may include an aging 
population and an increase in comorbidities. Furthermore, 
patients who previously were not treated despite the correct 
indications can now be treated. As the procedure became 
available in more hospitals, it might have been performed 
in more patients with acute ischemic stroke. However, if 
the difference in treatment outcomes is significant across 
different hospitals, there is a need to develop a system 
to transfer patients to a hospital where more effective 
treatment methods are available. If there is no significant 
difference in patient outcomes, allowing more hospitals to 
perform the MT procedure might allow more patients with 
acute ischemic stroke to be treated more effectively.
In this study, no comorbidity of any statistical difference 
per hospital type occurred other than atrial fibrillation 
and dyslipidemia. The mean value of SSI which reflect 
the severity of ischemic stroke was higher in non-tertiary 
hospitals during all periods, but the median values showed 
no statistical difference between hospitals except for the 
off-label period. Patient age was also not different between 
groups except during the transitional period. After the 
introduction of the stent-retriever, when MT was proven 
to be effective, the mortality rate of patients treated in non-
tertiary hospitals was still significantly higher than those in 
tertiary hospitals. However, in 2017, the 3-month mortality 
of non-tertiary hospital was decreased to make only 1.1% 
difference compared to the mortality of tertiary hospitals. 
The 3-month mortality of our study revealed similar results 
with the previous real-world clinical study, which had a 
mortality of 16% (19). The decrease in the difference of 
outcomes between hospitals may be contributed from an 
increase in the number of patients treated at hospitals whose 
annual volume is higher than the CSC threshold even in 
non-tertiary hospitals.
In this study, we could not exclude the possibility 
that a difference in the levels of hospital facilities and 
workforce might have increased the mortality rate in non-
tertiary hospitals compared with that in tertiary hospitals. 
A previous study reported a difference in mortality risk 
based related to hospital size and the presence or absence 
of medical resident training (20). Hospitals with stroke 
unit had a lower 1-year mortality rate than those without 
stroke unit (21). Such departments exist in all tertiary 
hospitals but not all non-tertiary hospitals. Whereas all 
tertiary hospitals had medical resident training, only 
one-third of non-tertiary hospitals, which is the primary 
focus of this study, had neurological and neurosurgical 
resident. This confirmed that there is a greater workforce 
participating in MT in tertiary hospitals than in non-
tertiary hospitals (22).
The statistical difference in rates of patients discharged 
home decreased to insignificance over time. When analyzed 
considering the number of procedures per year, patients 
were more likely to be discharged home from non-tertiary 
hospitals. Since MT was performed on patients with a 
wider standard in the tertiary hospitals than the non-
tertiary hospitals (22), there may be patients who did not 
recover enough to be discharged home even if the MT was 
successfully performed. The increase in the proportion of 
patients who received treatment in non-tertiary hospitals 
performing MT more than 18 cases per year may have 
affected the increase in the proportion of patients with 
good prognosis. The solitaire stent is an effective treatment 
tool that can be used by physicians with relatively little 
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experience (23), potentially explaining the potential 
improvement in non-tertiary hospitals that began to provide 
this treatment procedure. With the introduction of more 
effective treatment methods such as these, the number 
of patients with an expected favorable outcome may have 
increased regardless of the hospital they visited.
The rate of a good outcome in this study was higher 
than a study using other insurance claims data but was 
slightly lower when compared to the ratio of patients 
with modified Rankin scale (mRS) 0–2 at three months 
(7,8,24). In this study, some patients who were not 
discharged home may have received treatments in a 
rehabilitation hospital and then recovered to mRS 0–2 
at three months. Additionally, the number of patients 
with disability registration was lower than the mRS 
3–5 at three months, as previously reported. The ratio 
of patients with mRS 3–5 at three months was 38.6% 
in the meta-analysis of clinical studies using a stent-
retriever and 34.8% in real-world data (24,25). This is 
because some of the patients who were mRS 3–5 at three 
months may have recovered to the level where disability 
registration was unnecessary, related to long-term 
rehabilitation treatment after ischemic stroke, similar to 
patients who were not discharged home.
The incidence rate of cerebral hemorrhage with 
neurological deterioration was 4.4% in a meta-analysis (24). 
In real-world data, the rate was higher, 8% (26). Our study 
was based on insurance claims data that did not verify the 
imaging data. Instead, we identified the percentage of 
patients who underwent surgery for cerebral hemorrhage. 
This percentage was lower than the previous reports of 
cerebral hemorrhage incidence. This percentage did not 
include patients whose hemorrhage event was minor and 
who did not need surgical treatment or those whose event 
was too severe and did not receive surgery.
This study had some limitations. First, we used insurance 
claims data rather than real-world clinical data. Therefore, 
we could not identify related factors revealed by previous 
studies, such as the time from the symptom onset to the 
point of recanalization, the anatomical location of the 
occlusion, the result of recanalization, or initial NIHSS. 
Second, we were unable to verify the precise number of MT 
patients in the period when the solitaire stent—the most 
common MT instrument—was off-label and the period 
when the solitaire stent was not covered by insurance. 
Despite such limitations, our study has some advantages 
because it investigated nationwide dataset and used variables 
with high accuracies, such as hospital classifications, 
mortality, and disability registration.
Conclusions
Using data from the whole nation of South Korea, the 
present study confirmed the trend of an improved treatment 
outcome as the stent-retriever came into use in tertiary 
hospitals and non-tertiary hospitals. Currently, the range 
of indications for MT has been extended up to 24 hours 
after symptom onset. More ischemic stroke patients will 
be treated with MT hereafter. The results of this study 
suggest that fostering non-tertiary hospitals capable of 
thrombectomy in areas with poor access to tertiary hospitals 
serving as referral centers can be helpful to the national 
health system. More hospitals will be able to provide MT 
for the treatment of patients with acute ischemic stroke in 
the future, and as a consequence, more patients are expected 
to benefit from good prognosis by receiving proper 
treatment.
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